China Ketene Derivatives Market Size and Supply-Demand Analysis Report, 2026–2032

Tables and Figures Table 1: Global Sales Growth (CAGR) of Ketene Derivatives by Product Type, 2022 vs. 2026 vs. 2032 (in USD Million) Table 2: Global Sales Growth (CAGR) of Ketene Derivatives by Application, 2022 vs. 2026 vs. 2032 (in USD Million) Table 3: Current Development Status of the Ketene Derivatives Industry Table 4: Development Trends of Ketene Derivatives Table 5: Global Production Growth Rate (CAGR) of Ketene Derivatives by Major Region: 2022 vs. 2026 vs. 2032 (in Tons) Table 6: Global Production Volume of Ketene Derivatives by Major Region, 2022–2026 (in Tons) Table 7: Global Production Volume of Ketene Derivatives by Major Region, 2026–2032 (in Tons) Table 8: Global Production Market Share of Ketene Derivatives by Major Region, 2022–2026 Table 9: Global Production Volume of Ketene Derivatives by Major Region, 2026–2032 (in Tons) Table 10: Global Revenue Growth Rate (CAGR) of Ketene Derivatives by Major Region: 2022 vs. 2026 vs. 2032 (in USD Million) Table 11: Global Revenue from Ketene Derivatives by Major Region, 2022–2026 (in USD Million) Table 12: Global Revenue Market Share of Ketene Derivatives by Major Region, 2022–2026 Table 13: Global Revenue from Ketene Derivatives by Major Region, 2026–2032 (in USD Million) Table 14: Global Revenue Market Share of Ketene Derivatives by Major Region, 2026–2032 Table 15: Global Sales Volume of Ketene Derivatives by Major Region (in Tons): 2022 vs. 2026 vs. 2032 Table 16: Global Sales Volume of Ketene Derivatives by Major Region, 2022–2026 (in Tons) Table 17: Global Sales Volume Market Share of Ketene Derivatives by Major Region, 2022–2026 Table 18: Global Sales Volume of Ketene Derivatives by Major Region, 2026–2032 (in Tons) Table 19: Global Sales Volume Share of Ketene Derivatives by Major Region, 2026–2032 Table 20: Global Leading Manufacturers’ Ketene Derivatives Production Capacity, 2026–2026 (in Tons) Table 21: Global Leading Manufacturers’ Ketene Derivatives Sales Volume, 2022–2026 (in Tons) Table 22: Global Leading Manufacturers’ Ketene Derivatives Sales Volume Market Share, 2022–2026 Table 23: Global Leading Manufacturers’ Ketene Derivatives Revenue, 2022–2026 (in USD Million) Table 24: Global Leading Manufacturers’ Ketene Derivatives Revenue Market Share, 2022–2026 Table 25: Global Leading Manufacturers’ Ketene Derivatives Average Selling Price, 2022–2026 (in USD/Ton) Table 26: Global Top Ketene Derivatives Producers by Revenue in 2026 (in USD Million) Table 27: Leading Chinese Manufacturers’ Ketene Derivatives Sales Volume, 2022–2026 (in Tons) Table 28: Leading Chinese Manufacturers’ Ketene Derivatives Sales Volume Market Share, 2022–2026

Comprehensive In-Depth Analysis of the mRNA Industry Chain

Overseas leading bioprocessing equipment manufacturers dominate the mainstream market: Sartorius, Thermo Fisher, and GE Healthcare lead the global markets for single-use bioreactors, fully automated mRNA synthesis systems, and LNP microfluidic preparation equipment. Domestic manufacturers have rapidly achieved localization and commercialization of such equipment under China’s domestic substitution policy. Dongfu Long, Truking, and Saibridge Biotech have launched full suites of flexible mRNA manufacturing equipment covering the entire process—from plasmid fermentation and mRNA synthesis to LNP formulation. Sequencing and Neoantigen AI Algorithms MGI Tech: A global leader in gene sequencing instrumentation, providing high-throughput sequencing hardware infrastructure essential for personalized cancer vaccines; a core upstream sequencing infrastructure provider for China’s mRNA cancer vaccine sector. Exscientia: Its proprietary AI platform integrates end-to-end workflows—from mRNA sequence design to targeted LNP delivery—leveraging a lipid library of over 10 million compounds to enable precise multi-organ delivery, with accumulated data encompassing more than 10 million lipid structures and 100,000 experimental data points. JiawuYi: Possesses a globally exclusive yeast display technology platform capable of neoantigen target screening at the eukaryotic single-cell level, delivering precise neoantigen identification capabilities for personalized vaccines. 3D Medicines: Its proprietary AI + mRNA cancer vaccine platform, 3D-preciseAG, focuses on neoantigen prediction and sequence optimization, significantly enhancing the target precision of personalized vaccines. mRNA Midstream: CDMO + In-House Product Manufacturing Platforms The midstream R&D and manufacturing segment constitutes the core execution body of mRNA cancer therapy pipelines. It covers the full workflow—from sequence design and in-house delivery system development to formulation manufacturing and clinical advancement—with some leading enterprises also extending vertically into upstream core technology domains. Lonza Group, the global CDMO leader, commands approximately 35% of the global mRNA CDMO market—the largest share worldwide—and operates the world’s largest-scale commercial flexible mRNA production capacity. Other leading CDMO providers include Catalent and Recipharm. Domestic CDMO + In-House Product Dual-Strategy Players Domestic firms—including Everest Medicines, CSPC Innovation, Kanghua Bio, WuXi AppTec, CSPC Jushi Bio, and Shenxin Bio—are rapidly establishing proprietary mRNA manufacturing platforms. Traditional Chinese vaccine leaders—including Walvax Biotech, CanSinoBIO, and Ameile Vaccines—have built in-house mRNA production facilities; their prophylactic vaccine pipelines (e.g., for shingles and RSV) are progressing steadily and are currently preparing for Phase I clinical trials. Everest Medicines: Has established a localized AI + mRNA end-to-end platform. Its personalized cancer vaccine EVM16 is in Phase I clinical trials; initial human data presented at AACR 2026 showed neoantigen-specific T-cell responses in 8 out of 9 patients, and one patient with gastroesophageal junction carcinoma achieved partial response. Its off-the-shelf vaccine EVM14 has received IND approvals from both the U.S. FDA and China’s NMPA and will advance to Phase I clinical trials in the U.S. in Q1 2027. CSPC Innovation: Its AI-powered modular mRNA platform is operational. Its therapeutic vaccine SYS6026 for HPV-related high-grade squamous intraepithelial lesions (HSIL) is in Phase II trials; its shingles vaccine SYS6017 has advanced to Phase II; and its monkeypox vaccine SYS6037 received FDA clinical trial authorization in August 2026. It also markets the approved mRNA-related product Du’en Tai®.

Lonza sets new mid-term targets, confirms 2026 outlook

17 hours ago

Lonza confirmed its 2026 outlook and set new mid-term targets, planning to sell its Capsules & Health Ingredients business for $3 billion to become a pure-play drug manufacturer, targeting 10% to 13% organic sales growth and a high thirties core EBITDA margin.

reuters

2026-01-28

Lonza’s Full-Year 2025 Earnings Rose but Missed Estimates

2026-04-28

Argentina Hunts for LNG Imports for Winter in War-Wrecked Market

2026-10-13

Lonza sets new mid-term targets, confirms 2026 outlook

Lonza sets new mid-term targets, confirms 2026 outlook

FAQ